Ovid Therapeutics Inc. (OVID) earnings
OVID earnings moved a median of +3.24% by the close. Quarterly and annual OVID reports and results, each read against the price at its own news timestamp. Back to the OVID overview →
22 measured OVID earnings events.
Where these OVID earnings landedvs 22 measured OVID earnings reactions
| Middle 50% of OVID earnings reactions | -3.26% to +7.17% |
|---|---|
| Median reaction (to close) | +3.24% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 OVID earnings events with a measured close landed between -3.26% and +7.17%; 59% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Ovid Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.38% | +5.66% | |
| Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | Press release | -0.38% | +5.66% | |
| Form 10-Q Ovid Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.44% | +3.24% | |
| Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results | Press release | -1.44% | +3.24% | |
| Form 10-K Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.44% | |
| Form 10-Q Ovid Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +5.90% | +8.20% | |
| Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Press release | +5.90% | +8.20% | |
| Form 10-Q Ovid Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.19% | +52.62% | |
| Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results | Press release | -1.19% | +52.62% | |
| Form 10-Q Ovid Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -6.73% | -13.33% | |
| Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results | Press release | -6.73% | -13.33% | |
| Form 10-K/A Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -2.45% | -8.21% | |
| Form 10-K Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -1.96% | -3.92% | |
| Form 10-Q Ovid Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.80% | -10.14% | |
| Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results | Press release | -3.80% | -10.14% | |
| Form 10-Q Ovid Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.69% | +4.57% | |
| Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results | Press release | +0.69% | +4.57% | |
| Form 10-Q Ovid Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.36% | +7.67% | |
| Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results | Press release | +0.36% | +7.67% | |
| Form 10-K Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.28% | |
| Form 10-Q Ovid Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -0.56% | |
| Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates | Press release | +0.00% | -0.56% |
Keep exploring
More OVID: analyst actions → · SEC filings → · OVID overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lixte Biotechnology Holdings, Inc. (LIXT) | 239 | 0.00% | 48% |
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
| Cyclacel Pharmaceuticals, Inc. (CYCC) | 238 | -0.21% | 42% |
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.